Healthcare
Vivos Inc.(RDGL)
Live Price
Offline$0.0629
-2.66% today
1Y Change
-44.70%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $30.00M
- Revenue Growth
- +144.3%
- EPS Growth
- +4.2%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vivos Inc. (RDGL) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $0.06 and down 44.7% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of +144.3%, EPS growth of +4.2%, a dividend yield of 0.0%. What stands out right now is revenue +144.3%, EPS +4.2%, free cash flow -28.3% with operating margin -4629.4% and ROIC -178.3%. Valuation already assumes a fairly strong business story at price/sales 473.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RDGL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+144.3% vs +7.6% peer median
Operating Margin
Below sector median
-4629.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +144.3% and EPS at +4.2%, with operating margin around -4629.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -12.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +2.3% | +8.5% | โ |
2026 Mar 30, 2026 | โ | +0.0% | -7.2% | -22.5% |
2025 Nov 12, 2025 | โ | -1.2% | -38.9% | -27.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RDGL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RDGL Max Drawdown
-61.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RDGL and SPY.
Company Overview
Vivos Inc.
Other OTC
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
- Leadership
- Michael K. Korenko
- IPO Date
- Sep 2, 1998
- Employees
- 1
- Street Address
- 719 Jadwin Avenue
- Mailing
- Kennewick, WA, 99352
- Region
- Kennewick, WA, US
- Reporting Currency
- USD
- Investor Line
- 509 736 4000
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 473.7
- Price/Book
- 18.3
Growth
- Revenue
- +144.3%
- EPS
- +4.2%
- Free Cash Flow
- -28.3%
Profitability
- Gross Margin
- -87.4%
- Operating Margin
- -4629.4%
- Net Margin
- -4483.9%
- ROE
- -126.3%
- ROIC
- -178.3%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 14.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.